Securities Code: 002038 Securities Abbreviation: Shuanglu Pharmaceutical Announcement No.: 2026-004
Beijing Shuanglu Pharmaceutical Co., Ltd. 2025 Annual Report Summary
I. Important Notice
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial condition, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard Audit Opinion Notice □ Applicable Not Applicable
Board of Directors' Review of the Report Period's Profit Distribution Plan or Capital Reserve Transfer to Share Capital Plan ☑ Applicable Not Applicable
Whether to Transfer Capital Reserve to Share Capital □ Yes No
The profit distribution plan reviewed and approved by the company's board of directors is as follows: Based on 1,027,350,000 shares, a cash dividend of RMB 0.1 yuan (tax inclusive) per 10 shares will be distributed to all shareholders, with 0 bonus shares (tax inclusive), and no transfer of capital reserve to share capital.
Board of Directors' Resolution on the Report Period's Preferred Stock Profit Distribution Plan □ Applicable Not Applicable
II. Company Basic Information
- Company Profile
Stock Abbreviation: Shuanglu Pharmaceutical Stock Exchange: Shenzhen Stock Exchange Contact Person and Contact Information Name: Liang Shujie (Board Secretary) Office Address: Building 1, Bitong Garden, Fushi Road, Haidian District, Beijing Fax: 010-88795883 Email: lsj@slpharm.com.cn